New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.

The Mounjaro KwikPen, a multi-dose, prefilled device for single-patient use, is designed for convenient self-administration.

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...